Acute Coronary Syndrome Clinical Trials

Experimental: Tafolecimab group

Intensive LLT with tafolecimab (150 mg every 2 weeks) add to statin ± cholesterol absorption inhibitor.~The intervention of this trial is divided to two different stages to stimulate the comparison of SESS or step by step lipid lowering strategy, including 1) conventional LLT (statin ± cholesterol absorption inhibitor) with tafolecimab (150 mg every two weeks) or not till the end of 24 weeks, and 2) physician decisions according to the local guideline of cholesterol management (\< 1.8 mmol/L) in both groups from the start of 25th week till the end of 104 weeks. The statin refers to the maximal tolerated dose of statins every day. The cholesterol absorption inhibitors includes ezetimibe 10 mg and hybutimibe 10 mg every day. The statin or cholesterol absorption inhibitors use before enrollment will not be inhibited, while any injection of PCSK9 inhibitors within six months before enrollment will not be allowed. Other non-LDL-C lowering drugs can be also used and recorded in detail.

Active_comparator: control group

Conventional lipid lowering therapy with statin ± cholesterol absorption inhibitor.The statin refers to the maximal tolerated dose of statins every day. The cholesterol absorption inhibitors includes ezetimibe 10 mg and hybutimibe 10 mg every day. The statin or cholesterol absorption inhibitors use before enrollment will not be inhibited, while any injection of PCSK9 inhibitors within six months before enrollment will not be allowed. Other non-LDL-C lowering drugs can be also used and recorded in detail. After enrollment, a recommended statin and cholesterol absorption inhibitors using guideline to adjust LLT will be sent to each physicians to calculate how to make each patients achieve the LDL-C target. Adjustments will be permitted within 24 weeks only under predefined conditions: 1) the occurrence of serious LLT-related side effects, or 2) for patients in the control group, if their LDL-C levels are inadequately controlled via protocol-specified criteria at Visit 1 (Week 4).